COMPOSITION | |
---|---|
Sodium Valproate | 135MG | 333MG |
Valproic Acid | 58MG | 145MG |
Sodium Valproate Valproic Acid
VALPOVIB CR
SPECIFICATION | |
---|---|
FORM | TABLET |
PACKING | 10×10 |
PACKING TYPE | ALU |
MRP | – |
DESCRIPTION
N/A
Valproic acid, supplied as the sodium salt valproate semisodium or divalproex sodium, is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (CAS number: 76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.
SIDE EFFECTS
N/A
Oral, mouse: LD50 = 1098 mg/kg; Oral, rat: LD50 = 670 mg/kg. Symptoms of overdose may include coma, extreme drowsiness, and heart problems. The safety and tolerability of valproate in pediatric patients were shown to be comparable to those in adults.
INDICATION
N/A
For treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headache. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome.